Due to its constantly growing incidence, obesity is an increasingly serious social and medical problem. Available data on the use of novel oral anticoagulants in morbidly obese and obese patients are very limited. However, we tried to summarize the available knowledge on the use of anticoagulants in this subpopulation of patients in everyday clinical practice. Studies on the clinical use of anticoagulants provide a poor basis for any adjustment of doses in obese patients as compared to patients with normal body weight. In our opinion, further studies are required in this particular population
Pharmacologic prophylaxis of deep vein thrombosis and venous thromboembolism (VTE) is an important a...
Purpose: Direct oral anticoagulants (DOACs) are recommended in preference to vitamin K antagonists (...
While drug development has traditionally focused on the general population, the number of individual...
Obesity is recognized as one of the most important health problems facing the world today. The numbe...
Under-representation of obese patients in the subgroups of relevant studies raises concerns about th...
Obesity is a relatively common characteristic in modern western world populations and has a signific...
INTRODUCTION: The clinical outcomes of direct oral anticoagulant (DOAC) dosage regimens in morbid ob...
Direct oral anticoagulant (DOAC) agents are becoming the anticoagulation strategy of choice. However...
Increasing prevalence of cardiovascular disease and new evidence on the effects of antithrombotic th...
BACKGROUND: Selecting initial anticoagulant dose by patient weight for acute pulmonary embolism and ...
International audienceBACKGROUND: Selecting initial anticoagulant dose by patient weight for acute p...
Linda Tahaineh,1 Sahar M Edaily,1 Shadi F Gharaibeh2 1Department of Clinical Pharmacy, Faculty of Ph...
Background Randomized clinical trials comparing the efficacy and safety of direct oral anticoagulant...
Obesity plays an essential role in the safety of pharmacologic drugs. There is paucity of data for d...
Introduction: Due to fixed dosing of direct oral anticoagulants (DOACs), uncertainty exists about th...
Pharmacologic prophylaxis of deep vein thrombosis and venous thromboembolism (VTE) is an important a...
Purpose: Direct oral anticoagulants (DOACs) are recommended in preference to vitamin K antagonists (...
While drug development has traditionally focused on the general population, the number of individual...
Obesity is recognized as one of the most important health problems facing the world today. The numbe...
Under-representation of obese patients in the subgroups of relevant studies raises concerns about th...
Obesity is a relatively common characteristic in modern western world populations and has a signific...
INTRODUCTION: The clinical outcomes of direct oral anticoagulant (DOAC) dosage regimens in morbid ob...
Direct oral anticoagulant (DOAC) agents are becoming the anticoagulation strategy of choice. However...
Increasing prevalence of cardiovascular disease and new evidence on the effects of antithrombotic th...
BACKGROUND: Selecting initial anticoagulant dose by patient weight for acute pulmonary embolism and ...
International audienceBACKGROUND: Selecting initial anticoagulant dose by patient weight for acute p...
Linda Tahaineh,1 Sahar M Edaily,1 Shadi F Gharaibeh2 1Department of Clinical Pharmacy, Faculty of Ph...
Background Randomized clinical trials comparing the efficacy and safety of direct oral anticoagulant...
Obesity plays an essential role in the safety of pharmacologic drugs. There is paucity of data for d...
Introduction: Due to fixed dosing of direct oral anticoagulants (DOACs), uncertainty exists about th...
Pharmacologic prophylaxis of deep vein thrombosis and venous thromboembolism (VTE) is an important a...
Purpose: Direct oral anticoagulants (DOACs) are recommended in preference to vitamin K antagonists (...
While drug development has traditionally focused on the general population, the number of individual...